文献速递肝病消化道肿瘤与早癌

Arid1a调控晚期肝细胞癌对抗血管生成治疗的应答

Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2017-11-04

本研究探讨Arid1a在肝细胞癌中的抑癌机制及治疗价值,发现Arid1a缺失通过H3K27ac沉积导致Ang2异位表达促进血管生成和肿瘤进展,Arid1a缺陷肝癌对Ang2阻断和索拉非尼治疗敏感。

要点

  • Arid1a缺失见于晚期人肝细胞癌,与血管密度增加相关。
  • Arid1a缺失通过H3K27ac沉积于Ang2增强子/启动子导致Ang2异位表达。
  • Arid1a缺陷肝癌对Ang2阻断和索拉非尼治疗敏感。

核心结论

  • Arid1a缺失激活Ang2依赖的血管生成并促进肝细胞癌进展。
  • 肝细胞癌中Arid1a缺失赋予对Ang2阻断和索拉非尼治疗的敏感性。

研究设计与样本

  • 研究采用人及小鼠肝细胞癌免疫组化染色、定量PCR、ELISA或蛋白质印迹检测基因表达。
  • 用慢病毒shRNA建立Arid1a敲低肝细胞癌细胞系,基于血管密度量化肿瘤血管生成。
  • 用染色质免疫沉淀(ChIP)检测Arid1a对Ang2表达的调控。
  • 用裸鼠异种移植模型和二乙基亚硝胺(DEN)诱导的Arid1a条件性敲除小鼠肝细胞癌研究Arid1a缺失的促瘤功能。
  • 在体外和体内评估Ang2抗体和索拉非尼治疗的治疗价值。

主要发现

  • Arid1a缺失发生于晚期人肝细胞癌,与血管密度增加相关。
  • Arid1a缺失导致Ang2增强子和启动子处H3K27ac异常沉积,引起Ang2异位表达并促进肝细胞癌发展。
  • 在Arid1a缺陷肝细胞癌中阻断Ang2可显著降低血管密度和肿瘤进展。
  • 索拉非尼治疗抑制H3K27乙酰化和Ang2表达,可显著阻止Arid1a缺陷肝细胞癌的进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: AT-rich interaction domain 1a (Arid1a), a component of the chromatin remodeling complex, has emerged as a tumor suppressor gene. It is frequently mutated in hepatocellular carcinoma (HCC). However, it remains unknown how Arid1a suppresses HCC development and whether Arid1a deficiency could be exploited for therapy, we aimed to explore these questions. METHODS: The expression of Arid1a in human and mouse HCCs was determined by immunohistochemical (IHC) staining. Gene expression was determined by quantitative PCR, ELISA or western blotting. Arid1a knockdown HCC cell lines were established by lentiviral-based shRNA. Tumor angiogenesis was quantified based on vessel density. The regulation of angiopoietin (Ang2) expression by Arid1a was identified by chromatin immunoprecipitation (ChIP) assay. The tumor promoting function of Arid1a loss was studied with a xenograft model in nude mice and diethylnitrosamine (DEN)-induced HCC in Arid1a conditional knockout mice. The therapeutic values of Ang2 antibody and sorafenib treatment were evaluated both in vitro and in vivo. RESULTS: We demonstrate that Arid1a deficiency, occurring in advanced human HCCs, is associated with increased vessel density. Mechanistically, loss of Arid1a causes aberrant histone H3K27ac deposition at the angiopoietin-2 (Ang2) enhancer and promoter, which eventually leads to ectopic expression of Ang2 and promotes HCC development. Ang2 blockade in Arid1a-deficient HCCs significantly reduces vessel density and tumor progression. Importantly, sorafenib treatment, which suppresses H3K27 acetylation and Ang2 expression, profoundly halts the progression of Arid1a-deficient HCCs. CONCLUSIONS: Arid1a-deficiency activates Ang2-dependent angiogenesis and promotes HCC progression. Loss of Arid1a in HCCs confers sensitivity to Ang2 blockade and sorafenib treatment. LAY SUMMARY: AT-rich interaction domain 1a (Arid1a), is a tumor suppressor gene. Arid1a-deficiency promotes Ang2-dependent angiogenesis leading to hepatocellular carcinoma progression. Arid1a-deficiency also sensitizes tumors to Ang2 blockade by sorafenib treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hu C, Li W, Tian F, et al. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. J Hepatol. 2017. PMID: 29113912. doi:10.1016/j.jhep.2017.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。